How the Emergence of Immunotherapy has Impacted Practice Patterns for Treatment and Management of Merkel Cell Carcinoma
A retrospective review identified that clinical practice patterns have changed from 2002 to 2020, with the use of immunotherapy increasing as chemotherapy and radiation therapy use has decreased for patients with Merkel cell carcinoma.
This finding illustrates the shift in standard care for Merkel cell carcinoma (MCC) toward immunotherapy, reflecting broader changes in oncology practice patterns and influencing treatment decisions at both institutional and national levels.
Evidence level: Korai humán adat. Kis vagy feltáró emberi adat.
Related signals
- Recurrence and Survival Outcomes in Patients with Primary Merkel Cell Carcinoma with Positive, Negative, or Not Performed Sentinel Lymph Node Biopsy
- Repurposed pinworm medication shows ‘promise’ as treatment for Merkel cell carcinoma
- Merkel Cell Carcinoma: Epidemiology, Target, and Therapy
- The biology and treatment of Merkel cell carcinoma: current understanding and research priorities
- Avelumab in patients with chemotherapy‑refractory metastatic Merkel cell carcinoma: a multicentre, single‑group, open‑label, phase 2 trial